Methods and materials for evaluating cardiovascular conditions
AssigneeMayo Foundation for Medical Education and Research
InventorsStephen L. Kopecky, Jorg J. Goronzy, Cornelia M. Weyand
Life of this patent
Estimating the term…
Abstract
The invention provides methods and materials for evaluating cardiovascular conditions (e.g., angina conditions). Specifically, the invention provides methods and materials related to determining whether or not a mammal has at least one unstable plaque. The invention also provides kits for assessing cardiovascular conditions, substantially pure populations of cells, and methods of identifying compounds to treat life-threatening cardiovascular conditions (e.g., unstable angina).
Claims18
A method for determining whether or not a mammal has an unstable plaque, said method comprising determining whether or not a sample from said mammal contains an elevated level of a polypeptide, wherein said polypeptide is encoded by DNA responsive to an interferon-γ-activated transcription factor, and wherein said level indicates that said mammal contains said unstable plaque.
A method of assisting a person in determining whether or not a mammal has an unstable plaque, said method comprising:
- a) determining the level of a polypeptide in a sample from said mammal, wherein said polypeptide is encoded by DNA responsive to an interferon-γ-activated transcription factor, and
- b) communicating information about said level to said person, wherein an elevated level of said polypeptide in said sample indicates that said mammal contains said unstable plaque.
A method for determining whether or not a mammal is at risk for developing an unstable plaque, said method comprising determining whether or not a sample from said mammal contains an elevated level of a polypeptide, wherein said polypeptide is encoded by DNA responsive to an interferon-γ-activated transcription factor, and wherein said level indicates that said mammal is at risk for developing said unstable plaque.
A method of assisting a person in determining whether or not a mammal is at risk for developing an unstable plaque, said method comprising:
- a) determining the level of a polypeptide in a sample from said mammal, wherein said polypeptide is encoded by DNA responsive to an interferon-γ-activated transcription factor, and
- b) communicating information about said level to said person, wherein an elevated level of said polypeptide in said sample indicates that said mammal is at risk for developing said unstable plaque.
Dependencies are inferred from the claim text.